ABSTRACT
Background We need screening for RA patients at high risk of RA-ILD to prevent the associated decrease in life quality and survival. The proposed screenings disagree regarding the anti-citrullinated protein antibodies (ACPA) because of their inconsistent association across recent studies. Therefore, we hypothesized that meta-analysis of the published reports should reveal clues explaining the heterogeneity of results and that knowing them could help us progress in RA-ILD early detection.
Objectives We aimed to discover the factors accounting for the variability of the ACPA association in the published reports.
Methods We searched the Web of Science and PubMed databases for studies reporting ACPA in RA-ILD and RA-control groups. The identified studies were analyzed using meta-analysis and meta-regression to identify moderators of the ACPA association.
Results We found 513 unique records, containing 31 eligible data sets. The meta-analysis preceding the search for moderators showed a remarkable heterogeneity (pQ = 5.7 x 10-7). Appropriate tests showed that it was largely attributable (58.1 %) to an outlier study, which had recruited cases and controls in different place and time contexts. The exclusion of this outlier from subsequent analyses did not completely remove heterogeneity (pQ = 0.004). However, it permitted the identification of the patient classification method as a significant moderator: The 14 studies using chest CT showed stronger ACPA association with RA-ILD (OR = 3.05 [95%CI: 2.12-4.38]) than the 16 employing multifactorial criteria (1.55 [95%CI: 1.18-2.03]; p = 0.0047 for the contrast). This moderator accounted for the significant heterogeneity (pQ = 0.079), was robust in sensitivity analyses, and was the only one found.
Conclusions Our results validate the ACPA association with RA-ILD, reinforce the importance of study design, and suggest the need to consider if studies relying on chest CT for classification could be more fruitful in the search for RA-ILD biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been funded by Instituto de Salud Carlos III (ISCIII) through the PI23/000841 and RD21/0002/0003 projects, co-funded by the European Union under the Next Generation/Mecanismo para la Recuperacion y Resiliencia (MRR)/PRTR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
bartoszkaczm{at}gmail.com, Carmen.Conde.Muro{at}sergas.es
Data Availability
All data produced in the present work are contained in the manuscript and supplementary material
List of abbreviations
- ACPA
- anti-citrullinated protein antibodies
- ILD
- interstitial lung disease
- MUC5B
- mucin 5B gene
- OR
- odds ratio
- RA
- rheumatoid arthritis
- RA-ILD
- rheumatoid arthritis-associated interstitial lung disease
- AIC
- Akaike information criterion
- BIC
- Bayesian information criterion
- C-C
- case-control
- CHRT
- cohort
- CI
- confidence interval
- CT
- computed tomography
- HRCT
- high-resolution computed tomography
- LRT
- likelihood ratio test
- RF
- rheumatoid factor
